Caracterización de micelas de gangliósidos modificadas con moléculas de reconocimiento celular como estrategia de direccionamiento de fármacos
Parole chiave:
gangliósidos, micelas, ligandos, funcionalización, direccionamiento activo, terapia del cáncerAbstract
Una de las estrategias terapéuticas actuales contra el cáncer está orientada a mejorar la efectividad de los fármacos anticancerígenos existentes mediante el desarrollo de sistemas innovadores de transporte [13,14] que permitan modificar las características farmacocinéticas y de biodistribución de los principios activos. En esta línea, recientemente desarrollamos una nanoestructura micelar compuesta por monosialoglicoesfingolípidos (GM1) capaces de transportar fármacos hidrofóbicos (Ptx) y anfipáticos (Doxo) con alta eficiencia [80,81]. En este trabajo se planteó modificar estas micelas mediante la incorporación de una molécula de reconocimiento celular, con el objetivo de focalizar la acción citotóxica del fármaco vehiculizado hacia las células tumorales. Se evaluó la incorporación de moléculas de reconocimiento celular como el ácido fólico, anticuerpos, espermidina y lipoproteínas en las micelas de GM1, se caracterizaron las estructuras resultantes y se determinó la actividad farmacológica de las micelas modificadas. Algunas de las estructuras obtenidas, como GM1-espermidina y GM1-LDL mostraron diferencias significativas respecto a las micelas de GM1 en la internalización de fármacos frente a líneas tumorales in vitro. En el caso de GM1-IgG, si bien los resultados de actividad biológica in vitro de los fármacos vehiculizados no mostraron diferencias respecto al efecto de los mismos fármacos transportados en micelas de GM1 sin anticuerpos, se demostró que los anticuerpos forman complejos estables con las micelas, mantienen su capacidad de reconocimiento específico y no son desplazados por otras proteínas plasmáticas. Esto permite proponer al complejo GM1-IgG/fármaco como un sistema mixto, en el cual se puede combinar la acción efectora de los anticuerpos con el efecto biológico de los fármacos. Finalmente, se demostró que moléculas pequeñas como el ácido Fólico (AF) pueden ser incorporadas en la estructura micelar aplicando diferentes estrategias. En las condiciones evaluadas, las micelas modificadas con AF no revelaron diferencias significativas de actividad respecto a las micelas de GM1 frente a células tumorales RF positivas. El conjunto de resultados presentados en este trabajo nos permiten concluir que es posible modificar las micelas de GM1 con moléculas de reconocimiento celular de diferente naturaleza, posibilitando el diseño de micelas funcionales con características adecuadas para aplicaciones farmacológicas.Downloads
Riferimenti bibliografici
Instituto Nacional del Cáncer. Página web: www.cancer.gov/espanol.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell, 100:57-70, 2000. https://doi.org/10.1016/S0092-8674(00)81683-9
Hanahan D, Weinberg RA. The hallmarks of cancer: The next generation. Cell, 144:646-674, 2011. https://doi.org/10.1016/j.cell.2011.02.013
American Cancer Society. Global Cancer Facts & Figures, 3rd Edition, 2015.
Stewart BW and Wild CP. World Cancer Report 2014. IARC Non-series Publication. ISBN-13 9789283204299. 2014. http://www.iarc.fr
Triggle DJ. Drug development in the 21st century: medicines, man and receptors. Med Chem Res 13(3-4):238-248, 2004. https://doi.org/10.1007/s00044-004-0031-9
Brekke OH and Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. Vol. 2: 52-62, 2003. https://doi.org/10.1038/nrd984
Nagle T, Berg C, Nassr R, Pang K. The further evolution of biotech. Nat. Rev. Drug Discov. Vol. 2: 75-79, 2003.
https://doi.org/10.1038/nrd989
Harada H, Kizaka-Kondoh S and Hiraoka M. Antitumor Protein Therapy; Application of the Protein Transduction Domain to the Development of a Protein Drug for Cancer Treatment. Breast Cancer 13:16-26, 2006. https://doi.org/10.2325/jbcs.13.16
Weidle UH, Schneider B, Georges G and Brinkmann U. Genetically Engineered Fusion Proteins for Treatment of Cancer. Cancer Genomics & Proteomics 9: 357-372, 2012.
Castanotto D and Stein Cy A. Antisense oligonucleotides in cancer. Curr Opin Oncol 26:584-589, 2014. https://doi.org/10.1097/CCO.0000000000000127
Cavalli F. Cáncer: El gran desafío. Traducción de la edición alemana por César Alfredo Hernández Travieso. Editorial Ciencias Médicas, Cuba, 2012.
Alexis F et al. Nanoparticle Technologies for Cancer Therapy. Drug Delivery, Handbook of Experimental Pharmacology 197, 2009. doi:10.1007/978-3-642- 00477-3_2.
Torchilin VP. Nanoparticulates Drug Carriers. Imperial College Press, 2006. https://doi.org/10.1142/9781860949074
NNI. What is nanotechnology? Available online: http://www.nano.gov/nanotech-101/what/definition.
Mousa SA and Bharali DJ. Nanotechnology-Based Detection and Targeted Therapy in Cancer: Nano-Bio Paradigms and Applications. Cancers 3: 2888-2903, 2011. https://doi.org/10.3390/cancers3032888
Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekarand Majoros SS, Thomas TP, Balogh LP, Khan MK and Baker JR. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res, 65:5317-5324, 2005. https://doi.org/10.1158/0008-5472.CAN-04-3921
Pastorin G, Wu W, Wieckowski S, Briand JP, Kostarelos K, Prato M and Bianco A. Double functionalization of carbon nanotubes for multimodal drug delivery. Chem Commun 11:1182-1184, 2006. https://doi.org/10.1039/b516309a
Gidwani B and Vyas A. A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs. BioMed Research International. Article ID 198268, 2015. https://doi.org/10.1155/2015/198268
Flenniken ML, Willits DA, Harmsen AL, Liepold LO, Harmsen AG, Young MJ, and Douglas T. Melanoma and lymphocyte cell-specific targeting incorporated into heat shock protein cage architecture. Chemistry & Biology, 13: 161-170, 2006. https://doi.org/10.1016/j.chembiol.2005.11.007
Callaghan R, Luk F and Bebawy M. Inhibition of the Multidrug Resistance PGlycoprotein: Time for a Change of Strategy?. Drug Metab Dispos 42:623-631, 2014. https://doi.org/10.1124/dmd.113.056176
Dong X and Mumper RJ. Nanomedicinal strategies to treat multidrugresistant tumors: current progress. Nanomedicine; 5(4): 597-615, 2010. https://doi.org/10.2217/nnm.10.35
Hoosain FG et al. Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy. BioMed Research International. Article ID 484963, 2015. https://doi.org/10.1155/2015/484963
Ma L, Kohli M, and Smith A. Nanoparticles for Combination Drug Therapy. ACS Nano. 7(11): 9518-9525, 2013.
https://doi.org/10.1021/nn405674m
Zhang RX, Wong HL, Xue HY, Eoh JY and Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives. Journal of Controlled Release Vol 240: 489-503, 2016. https://doi.org/10.1016/j.jconrel.2016.06.012
Baetke SC, Lammers T and Kiessling F. Applications of nanoparticles for diagnosis and therapy of cancer. Br J Radiol 88: 20150207, 2015. https://doi.org/10.1259/bjr.20150207
Fan Z, Fu PP, Yu H and Ray PC. Theranostic nanomedicine for cancer detection and treatment. Journal of Food and Drug Analysis, Vol. 22: 3-17, 2014. https://doi.org/10.1016/j.jfda.2014.01.001
Kievit FM and Zhang M. Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery across Biological Barriers. Adv Mater, 23: 217 247, 2011. https://doi.org/10.1002/adma.201102313
Patel A, Patel M, Yang X, and Mitra AK. Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles. Protein Pept Lett; 21: 1102-1120, 2014. https://doi.org/10.2174/0929866521666140807114240
Gdowski A, Ranjan A, Mukerjee A and Vishwanatha J. Development of Biodegradable Nanocarriers Loaded with a Monoclonal Antibody. Int. J. Mol. Sci. 16, 3990-3995, 2015. https://doi.org/10.3390/ijms16023990
Solaro R, Chiellini F and Battisti A. Targeted Delivery of Protein Drugs by Nanocarriers. Materials 3, 1928-1980, 2010. https://doi.org/10.3390/ma3031928
Jeong JH, Park TG and Kim SH. Self-Assembled & Nanostructured siRNA Delivery Systems. Pharmaceutical Research, 28(9), 2072-2085, 2011. https://doi.org/10.1007/s11095-011-0412-y
Mangraviti et al. Polymeric Nanoparticles for Nonviral Gene Therapy Extend Brain Tumor. ACS Nano 9 (2), 1236-1249, 2015. https://doi.org/10.1021/nn504905q
Veronese FM and Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today 10: 1451-1458, 2005. https://doi.org/10.1016/S1359-6446(05)03575-0
Shi M, Luc J and Shoichet MS. Organic nanoscale drug carriers coupled with ligands for targeted drug delivery in cancer. Journal. Mater. Chem., 19: 5485 5498, 2009. https://doi.org/10.1039/b822319j
Zhao et al. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. International Journal of Nanomedicine 5: 1-9, 2010.
Yu et al. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 27(7): 286-298, 2010. https://doi.org/10.3109/09687688.2010.521200
Kobayashi H, Watanabe R and Choyke PL. Improving conventional enhanced permeability and retention effect. Theranostics, 4:81-89, 2014. https://doi.org/10.7150/thno.7193
Yin H, Liao L, Fang J. Enhanced Permeability and Retention (EPR) Effect Based Tumor Targeting: The Concept, Application and Prospect. JSM Clin Oncol Res 2(1): 1010, 2014.
Maeda H, Nakamura H and Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Advanced Drug Delivery Reviews 65: 71-79, 2013. https://doi.org/10.1016/j.addr.2012.10.002
Matsumura Y and Maeda H. A new concept for macromolecular therapeutics in cancer- chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:6387-92, 1986. doi: 10.7150/thno.7193
Lollo G, Rivera-Rodríguez G, Torres D, y Alonso MJ. Nanoterapias oncológicas: aplicaciones actuales y perspectivas futuras. Anales de la Real Academia Nacional de Farmacia, 368: 76-98, 2011.
Weissig V, Pettinger TK and Murdock N. Nanopharmaceuticals (part 1): products on the market. International Journal of Nanomedicine 9: 4357-4373, 2014. https://doi.org/10.2147/IJN.S46900
Gelderblom H, Verweij J, Nooter K, and Sparreboom A. "Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation," European Journal of Cancer, Vol. 37, no. 13, 1590-1598, 2001. https://doi.org/10.1016/S0959-8049(01)00171-X
Desai N et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, abi-007, compared with cremophor-based paclitaxel. Clin Cancer Res, 12:1317-1324, 2006. https://doi.org/10.1158/1078-0432.CCR-05-1634
Fukunaga-Kalabis M and Herlyn M. Unraveling mysteries of the multifunctional protein sparc. J Invest Dermatol, 127: 2497-2498, 2007. https://doi.org/10.1038/sj.jid.5701050
Hawkins MJ, Soon-Shiong P and Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Del Rev, 60: 876-885, 2008. https://doi.org/10.1016/j.addr.2007.08.044
Schütz CA, Juillerat-Jeanneret L, Mueller H, Lynch I and Riediker M. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine 8(3): 449-467, 2013. https://doi.org/10.2217/nnm.13.8
Su-Eon Jin et al. Targeted Delivery System of Nanobiomaterials in Anticancer Therapy: From Cells to Clinics. BioMed Research International, Article ID 814208, 2014. https://doi.org/10.1155/2014/814208
Danhier F et al. Strategies to improve the EPR effect for the delivery of anti-cancer nanomedicines. Cancer Cell & Microenvironment 2: e808, 2015. doi:10.14800/ccm.808
Prabhakar et al. Challenges and key considerations of the enhanced permeability and retention (EPR) effect for nanomedicine drug delivery in oncology. Cancer Res. 73(8): 2412-2417, 2013. https://doi.org/10.1158/0008-5472.CAN-12-4561
Nehoff H et al. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. International Journal of Nanomedicine 9:2539-2555, 2014. https://doi.org/10.2147/IJN.S47129
Durymanov MO, Rosenkranz AA and Sobolev AS. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines. Theranostics 5(9): 1007-1020, 2015. https://doi.org/10.7150/thno.11742
Arachchige et al. Advanced Targeted Nanomedicine. J Biotechnol. 202: 88 97, 2015. https://doi.org/10.1016/j.jbiotec.2015.01.009
Laurent S and Mahmoudi M. Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer. Int J Mol Epidemiol Genet 2(4):367-390, 2011. https://doi.org/10.1021/cn100100e
Boyer C, Whittaker MR, Bulmus V, Liu J and Davis TP. The design and utility of polymer-stabilized iron oxide nanoparticles for nanomedicine applications. NPG Asia Mater. 2(1) 23-30, 2010. https://doi.org/10.1038/asiamat.2010.6
Grange C , Geninatti-Crich S , Esposito G , Alberti D , Tei L, Bussolati B , Aime S and Camussi G. Combined Delivery and Magnetic Resonance Imaging of Neural Cell Adhesion Molecule-Targeted Doxorubicin Containing Liposomes in Experimentally Induced Kaposi's Sarcoma. Cancer Res; 70(6), 2010. https://doi.org/10.1158/0008-5472.CAN-09-2821
Srinivasan M, Rajabi M and Mousa SA. Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer Therapy. Nanomaterials 5: 1690 1703, 2015. https://doi.org/10.3390/nano5041690
Sun L et al. Strategies of polymeric nanoparticles for enhanced internalization in cancer therapy. Colloids and Surfaces B: Biointerfaces 135: 56 72, 2015. https://doi.org/10.1016/j.colsurfb.2015.07.013
Wu X, Chen J, Wu M, Zhao JX. Aptamers: Active Targeting Ligands for Cancer Diagnosis and Therapy. Theranostics 5(4): 322-344, 2015. https://doi.org/10.7150/thno.10257
Zwicke GL et al. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Reviews 3: 18496, 2012. https://doi.org/10.3402/nano.v3i0.18496
Lencioni R, Cioni D. RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma Hepatic Oncology. Published online June 10, 2016. https://doi.org/10.2217/hep-2016-0005
Marqués-Gallego P and Kroon AIPM. Ligation Strategies for Targeting Liposomal Nanocarriers. BioMed Research International Vol. 2014, Article ID 129458, 2014. https://doi.org/10.1155/2014/129458
Karra N and Benita S. The Ligand Nanoparticle Conjugation Approach for Targeted Cancer Therapy. Current Drug Metabolism Vol. 13: 22-41, 2012. https://doi.org/10.2174/138920012798356899
Werengowska-Ciecwierz K et al. The Chemistry of Bioconjugation in Nanoparticles-Based Drug Delivery System. Advances in Condensed Matter Physics Vol, 2015, Article ID 198175, 2015. https://doi.org/10.1155/2015/198175
Kim JH and Yoon JY. Protein adsorption on polymer particles. Encyclopedia of Surface and Colloid Science, 2002.
Bertrand N et al. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev; 2013. https://doi.org/10.1016/j.addr.2013.11.009
Lu Y and Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Advanced Drug Delivery Reviews 54: 675-693, 2002. https://doi.org/10.1016/S0169-409X(02)00042-X
Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Current Opinion in Chemical Biology 3: 256-62, 2009. https://doi.org/10.1016/j.cbpa.2009.03.022
Lutz RJ. Targeting the folate receptor for the treatment of ovarian cancer. Translational Cancer Research 4(1): 118-126, 2015. doi:10.3978/j.issn.2218- 676X.2015.01.04
Choi KY et al. Hyaluronic acid-based nanocarriers for intracellular targeting: Interfacial interactions with proteins in cancer. Colloids and Surfaces B: Biointerfaces 99: 82- 94, 2012. https://doi.org/10.1016/j.colsurfb.2011.10.029
Arruebo M, Valladares M and González-Fernández A. Antibody-Conjugated Nanoparticles for Biomedical Applications. Journal of Nanomaterials Vol. 2009, Article ID 439389, 2009. https://doi.org/10.1155/2009/439389
Gerber H-P, Senter PD and Grewal IS. Antibody drug-conjugates targeting the tumor vasculature: Current and future developments. mAbs. 1(3):247-253, 2009. https://doi.org/10.4161/mabs.1.3.8515
Xu S et al. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev. 65(1):121-138, 2013. https://doi.org/10.1016/j.addr.2012.09.041
Low K, Wacker M, Wagner S, Langer K and von Briesen H. Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells. Nanomedicine: NBM xx: 1-10, 2011. https://doi.org/10.1016/j.nano.2010.12.003
Sun B et al. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29: 475-486, 2008. https://doi.org/10.1016/j.biomaterials.2007.09.038
Gilad Y, Firer M and Gellerman G. Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells. Biomedicines 4 (11), 2016. https://doi.org/10.3390/biomedicines4020011
Wang F, Li Y, Shen Y, Wang A, Wang S and Xie T. The Functions and Applications of RGD in Tumor Therapy and Tissue Engineering. Int. J. Mol. Sci. 14: 13447-13462, 2013. https://doi.org/10.3390/ijms140713447
Farokhzad OC, Jon S, Khademhosseini A, Tran TN, LaVan DA and Langer R. Nanoparticle-Aptamer Bioconjugates: A New Approach for Targeting Prostate Cancer Cells. Cancer Research 64: 7668 -7672, 2004. https://doi.org/10.1158/0008-5472.CAN-04-2550
Leonhard V, Alasino RV, Bianco ID, Garro AG, Heredia V and Beltramo DM. Self-assembled micelles of monosialogangliosides as nanodelivery vehicles for taxanes. Journal of Controlled Release 162: 619-627, 2012.
https://doi.org/10.1016/j.jconrel.2012.07.031
Leonhard V, Alasino RV, Bianco ID, Garro AG, Heredia V and Beltramo DM. Biochemical characterization of the interactions between doxorubicin and lipidic GM1 micelles with or without paclitaxel loading. International Journal of Nanomedicine 10: 3377-3388, 2015. https://doi.org/10.2147/IJN.S77153
Heredia V, Alasino RV, Leonhard V, Garro AG, Maggio B and Beltramo DM. Sialoganglioside Micelles for Enhanced Paclitaxel Solubility: In Vitro Characterization. Journal of Pharmaceutical Sciences 105: 268-275, 2016. https://doi.org/10.1016/j.xphs.2015.10.029
Leonhard V, Alasino RV, Bianco ID, Garro AG, Heredia V and Beltramo DM. Biochemical Characterization of GM1 Micelles-Amphotericin B Interaction. Current Drug Delivery Vol. 12, No. 0, 2015. https://doi.org/10.2174/1567201812666150316113355
Sonnino S, Mauri L, Chigorno V, Prinetti A. Gangliosides as components of lipid membrane domains. Glycobiology, 17 (1) 1-13, 2006. https://doi.org/10.1093/glycob/cwl052
Kolter T. Ganglioside Biochemistry. International Scholarly Research Network ISRN Biochemistry Vol. 2012, Article ID 506160, 2012. https://doi.org/10.5402/2012/506160
Ulrich-Bott B, Wiegandt H. Micellar properties of glycosphingolipids in aqueous media. J Lipid Res, 25: 1233-1245, 1984. https://doi.org/10.1016/S0022-2275(20)34467-9
Formisano S, Johnson ML, Lee G, Aloj SM, Edelhoch H. Critical Micelle Concentrations of Gangliosides. Biochemistry, 18 (6) 1119-1124, 1979. https://doi.org/10.1021/bi00573a028
Chandler D. Interfaces and the driving force of hydrophobic assembly. Nature, Vol 437: 640-647, 2005. https://doi.org/10.1038/nature04162
Schengrund CL. Gangliosides: glycosphingolipids essential for normal neural development and function. Cell Press: Trends in Biochemical Sciences 40(7):397-406, 2015. https://doi.org/10.1016/j.tibs.2015.03.007
Yu RK, Tsai YT and Ariga T. Functional roles of gangliosides in neurodevelopment-An overview of recent advances. Neurochem Res. 37(6): 1230-1244, 2012. https://doi.org/10.1007/s11064-012-0744-y
Yu et al. Structures, biosynthesis, and functions of gangliosides - An overview. J Oleo Sci. 60(10): 537-544, 2011.
https://doi.org/10.5650/jos.60.537
Posse de Chaves E, Sipione S. Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS Letters 584: 1748 1759, 2010. https://doi.org/10.1016/j.febslet.2009.12.010
Morris NP, Consiglio E, Kohn LD, Habig WH, Hardegree MC and Helting TB. Interaction of Fragments B and C of Tetanus Toxin with Neural and Thyroid Membranes and with Gangliosides. The Journal of Biological Chemistry Vol. 255(13): 6071-6076, 1980. https://doi.org/10.1016/S0021-9258(18)43702-7
van Buuren MM. Sialic acid as a receptor for viruses and bacterial toxins. Biomedical Sciences - Immunity & Infection, 2009.
Tyurin VA, Tyurina YY, Avrova N. Ganglioside-dependent factor, inhibiting lipid peroxidation in rat brain. Neurochem Int, 20: 401-407, 1992. https://doi.org/10.1016/0197-0186(92)90055-V
Avrova NF, Zakharov IO, Tyurin VA, Tyurina YY, Gamaley IA, et al. Different metabolic effects of ganglioside GM1 in brain synaptosomes and phagocytic cells. Neurochem Res, 27: 751-759, 2002. https://doi.org/10.1023/A:1020296605444
Ledeen R, Wu G. New findings on nuclear gangliosides: overview on metabolism and function. J Neurochem. 116(5):714-720, 2011. https://doi.org/10.1111/j.1471-4159.2010.07115.x
Ariga T, McDonald MP and Yu RK. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease-a review. Journal of Lipid Research Vol 49:1157-1175, 2008. https://doi.org/10.1194/jlr.R800007-JLR200
Mocchetti I. Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. CMLS, Cell. Mol. Life Sci. 62: 2283-2294, 2005. https://doi.org/10.1007/s00018-005-5188-y
Skaper SD, Leon A and Toffano G. Ganglioside Function in the Development and Repair of the Nervous System. Molecular Neurobiology Vol 3:173-199, 1989. https://doi.org/10.1007/BF02935630
Li S, Xiao N, Zhang X, et al. Effects of exogenous ganglioside-1 on learning and memory in a neonatal rat model of hypoxia-ischemia brain injury. Neural Regen Res. 3(9):1004-1009, 2008.
Zou et al. Penetration of blood-brain barrier and antitumor activity and nerve repair in glioma by doxorubicin-loaded monosialoganglioside micelles system. International Journal of Nanomedicine 12: 4879-4889, 2017. https://doi.org/10.2147/IJN.S138257
Wu G, Lu ZH, Kulkarni N, Amin R, Ledeen RW. Mice lacking major brain gangliosides develop Parkinsonism. Neurochem Res. 36(9): 1706-1714, 2011. https://doi.org/10.1007/s11064-011-0437-y
Miazek K., Lebecque S., Hamaidia M. et al. Sphingolipids: promising lipidclass molecules with potential applications for industry. A review. Biotechnol. Agron. Soc. Environ. 20(S1): 321-336, 2016. https://doi.org/10.25518/1780-4507.13071
WO2011113981 A1. Inventores: Beltramo D, Leonhard V, Alasino RV, Bianco I. Doc Type: Patent Application ID: lens.org/008-873-544-655-106. Water-soluble pharmaceutical composition comprising at least one therapeutically active substance having hydrophobic properties and at least one compound selected from among sialoglycosphingolipids, glycosphingolipids or a mixture of sialoglycosphing, 2011.
Leonhard et al. Selective Binding of Albumin to GM1 Ganglioside Micelles Containing Paclitaxel. J Nanomed Nanotechol 4: 159, 2013. https://doi.org/10.4172/2157-7439.1000159
Pegg AE. Mammalian polyamine metabolism and function. IUBMB Life; 61: 880-894, 2009. https://doi.org/10.1002/iub.230
Casero RA, Nowotarski SL, Woster PM. Polyamines and cancer: implications for chemotherapy and chemoprevention. Expert reviews in molecular medicine. University Press; Cambridge 2013. https://doi.org/10.1017/erm.2013.3
Casero RA, Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 6: 373-390, 2007. https://doi.org/10.1038/nrd2243
Esteves-Souza A, Rocha GC, Araujo LK, et al. Antitumoral activity of new polyaminenaphthoquinone conjugates. Oncol Rep 20: 225-231, 2008. https://doi.org/10.3892/or.20.1.225
Martinez ME, O'Brien TG, Fultz KE, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proceedings of the National Academy of Sciences. 100: 7859-7864, 2003. https://doi.org/10.1073/pnas.1332465100
Gerner EW, Meyskens FL. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4: 781-792, 2004. https://doi.org/10.1038/nrc1454
Soda K. The mechanisms by which polyamines accelerate tumor spread. J Exp Clin Cancer Res 30:95, 2011. https://doi.org/10.1186/1756-9966-30-95
Palmer AJ and Wallace HM. The polyamine transport system as a target for anticancer drug development. Amino Acids 38 (2):415-422, 2010. https://doi.org/10.1007/s00726-009-0400-2
D'Agostino L. Polyamine uptake by human colon carcinoma cell line CaCo2. Digestion 46 Suppl 2: 352-9, 1990. https://doi.org/10.1159/000200408
Morgan DM. Uptake of polyamines by human endothelial cells. Characterization and lack of effect of agonists of endothelial function. Biochem J 286: 413-417, 1992. https://doi.org/10.1042/bj2860413
Palmer AJ, Ghani RA, Kaur N, Phanstiel O, Wallace HM. A putrescineanthracene conjugate: a paradigm for selective drug delivery. Biochem J 424: 431-8, 2009. https://doi.org/10.1042/BJ20090815
Holley JL, Mather A, Wheelhouse RT, et al. Targeting of Tumor Cells and DNA by a Chlorambucil-Spermidine Conjugate. Cancer Res 52: 4190-4195, 1992.
Seiler N. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 2. Structural analogues and derivatives. Curr Drug Targets 4: 565-85, 2003. https://doi.org/10.2174/1389450033490876
Porter CV, Bergeron RJ, Stolowich NJ. Biological properties of N4- spermidine derivatives and their potential in anticancer chemotherapy. Cancer Res 42: 4072-4078, 1982.
Hermanson GT. Bioconjugate Techniques, Academic Press; London 1996. https://doi.org/10.1016/B978-012342335-1/50012-9
Raspaud E, de la Cruz OM, Sikorav JL, Livolant F. Precipitation of DNA by Polyamines: A Polyelectrolyte Behavior. Biophys J 74: 381-393, 1998. https://doi.org/10.1016/S0006-3495(98)77795-1
Honga K, Zhenga W, Bakerb A, Papahadjopoulosa D. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery. FEBS Letters 400: 233-237, 1997. https://doi.org/10.1016/S0014-5793(96)01397-X
Azzama T, Eliyahua H, Makovitzkia A, Linialb M, Domb AJ. Hydrophobized dextran-spermine conjugate as potential vector for in vitro gene transfection. J Cont Release 96: 309-323, 2004. https://doi.org/10.1016/j.jconrel.2004.01.022
Kim B-K, Seu Y-B, Bae Y-U, et al. Efficient Delivery of Plasmid DNA Using Cholesterol-Based Cationic Lipids Containing Polyamines and Ether Linkages. Int J Mol Sci 15: 7293-7312, 2014. https://doi.org/10.3390/ijms15057293
Vijayanathan V, Agostinelli E, Thomas T, Thomas TJ. Innovative approaches to the use of polyamines for DNA nanoparticle preparation for gene therapy. Amino Acids 46 (3): 499-509, 2014. https://doi.org/10.1007/s00726-013-1549-2
Viola BM, Abraham TE, Arathi DS, Sreekumar E, Pillai MR, Thomas TJ, Pillai CKS. Synthesis and characterization of novel water-soluble polyamide based on spermine and aspartic acid as a potential gene delivery vehicle. Exp Poly Lett 2 (5): 330-338, 2008. https://doi.org/10.3144/expresspolymlett.2008.39
Blagbrough IS, Geall AJ, Neal AP. Polyamines and novel polyamine conjugates interact with DNA in ways that can be exploited in non-viral gene therapy. Biochem Soc Trans 31(2): 397-406, 2003. https://doi.org/10.1042/bst0310397
Wallace HM, Fraser AV, Hughes A. A perspective of polyamine metabolism. Biochem J 376: 1-14, 2003. https://doi.org/10.1042/bj20031327
Phanstiel O, Kaur N and Delcros JG. Structure-activity investigations of polyamine-anthracene conjugates and their uptake via the polyamine transporter. Amino Acids 33: 305-313, 2007. https://doi.org/10.1007/s00726-007-0527-y
Holley J, Mather A, Cullis P, Symons MR, Wardman P, Watt RA, Cohen GM. Uptake and cytotoxicity of novel nitroimidazolepolyamine conjugates in Ehrlich ascites tumour cells. A Biochem Pharmacol 43(4):763-9, 1992. https://doi.org/10.1016/0006-2952(92)90241-A
Criss WE. A Review of Polyamines and Cancer. Turk J Med Sci 33: 195 205, 2003.
Ehrlich P. Collected studies on immunity. New York: J. Wiley & Sons, 1906.
Blanco et al. Multifunctional Micellar Nanomedicine for Cancer Therapy. Exp Biol Med 234(2): 123-131, 2009. https://doi.org/10.3181/0808-MR-250
Kocbek P et al. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. Journal of Controlled Release 120, 18-26, 2007. https://doi.org/10.1016/j.jconrel.2007.03.012
Balthasar S et al. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 26: 2723-2732, 2005. https://doi.org/10.1016/j.biomaterials.2004.07.047
Yousefpour et al. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. International Journal of Nanomedicine 6, 1977-1990, 2011. https://doi.org/10.2147/IJN.S21523
Yu MK, Park J. and Jon S. Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy. Theranostics 2(1), 3-44, 2012. https://doi.org/10.7150/thno.3463
Fahmy TM, Fong PM, Goyal A and Saltzman WM. Targeted for drug delivery, Mater. Today 8 (8), 18-26, 2005. https://doi.org/10.1016/S1369-7021(05)71033-6
Torchillin VP et al. Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs. PNAS 100 (10), 6039-6044, 2003. https://doi.org/10.1073/pnas.0931428100
Low K, Wacker M, Wagner S, Langer K and von Briesen H. Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells. Nanomedicine: NBM; xx: 1-10, 2011. https://doi.org/10.1016/j.nano.2010.12.003
Lowry O H, Rosebrough N J, Farr A L & Randall R J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265, 1951. https://doi.org/10.1016/S0021-9258(19)52451-6
Vermeer AWP and Norde W. The Thermal Stability of Immunoglobulin: Unfolding and Aggregation of a Multi-Domain Protein. Biophysical Journal Vol 78: 394-404, 2000. https://doi.org/10.1016/S0006-3495(00)76602-1
Vermeer AWP et al. The Unfolding/Denaturation of Immunogammaglobulin of Isotype 2b and Its Fab and Fc Fragments. Biophysical Journal Vol 79: 2150-2154, 2000. https://doi.org/10.1016/S0006-3495(00)76462-9
Cantú L, Corti M, Del Favero E, Muller E, Raudino A, Sonnino S. Thermal hysteresis in ganglioside micelles investigated by differential scanning calorimetry and light-scattering. Langmuir 15: 4975-4980, 1999. https://doi.org/10.1021/la981355n
Hirai M and Takizawa T. Intensive extrusion and occlusion of water in ganglioside micelles with thermal reversibility. Biophysical Journal 74: 3010 3014, 1998. https://doi.org/10.1016/S0006-3495(98)78008-7
Orthaber D, Glatter O. Time and temperature dependent aggregation behavior of the ganglioside GM1 in aqueous solution. Chem. Phys. Lipids, 92(1): 53-62, 1998. https://doi.org/10.1016/S0009-3084(98)00010-3
Scott AM, Wolchok and Old LJ. Antibody therapy of cancer. Nature Reviews Cancer 12: 278-287. 2012. https://doi.org/10.1038/nrc3236
Trail PA. Antibody Drug Conjugates as Cancer Therapeutics. Antibodies 2: 113-129, 2013. https://doi.org/10.3390/antib2010113
Weiner LM, Surana R and Wang S. Antibodies and cancer therapy: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 10(5): 317 327, 2010. https://doi.org/10.1038/nri2744
Sharkey RM and Goldenberg DM. Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates. CA Cancer J Clin 56:226-243, 2006. https://doi.org/10.3322/canjclin.56.4.226
Van Berkel TJ. Drug targeting: application of endogenous carriers for site specific delivery of drug. Journal of Controlled Release 24: 145-155, 1993. https://doi.org/10.1016/0168-3659(93)90174-4
Kader A and Pater A. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. Journal of Controlled Release 80: 29-44, 2002. https://doi.org/10.1016/S0168-3659(01)00536-3
Lou B, Liao XL, Wu MP, Cheng PF, Yin CY, Fei Z. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J Gastroenterol 11(7): 954-959, 2005. https://doi.org/10.3748/wjg.v11.i7.954
Lacko AG, Sabnis NA, Nagarajan B and McConathy WJ. HDL as a drug and nucleic acid delivery vehicle. Front. Pharmacol. 6: 247, 2015. https://doi.org/10.3389/fphar.2015.00247
Kader A et al. Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. Journal of Controlled Release 55: 231-243, 1998. https://doi.org/10.1016/S0168-3659(98)00052-2
Foroozesh M and Zarrin A. A Safe, Versatile and Translation-prone Strategy for Using Circulating Lipoproteins as Endogenous Drug Delivery Systems. Irn J Med Hypotheses Ideas 4: 15, 2010.
Ng KK et al. Lipoprotein-Inspired Nanoparticles for Cancer Theranostics. Accounts of Chemical Research, Vol. 44(10): 1105-1113, 2011. https://doi.org/10.1021/ar200017e
Goldstein JL and Brown MS. The Low-Density Lipoprotein Pathway and Its Relation to Atherosclerosis. Annual Review of Biochemistry, 46: 897-930, 1977. https://doi.org/10.1146/annurev.bi.46.070177.004341
Brown MS and Goldstein JL. Receptor-mediated endocytosis: Insights from the lipoprotein receptor system. Proc. Nati. Acad. Sci. USA Vol. 76, No. 7, pp. 3330-3337, 1979. https://doi.org/10.1073/pnas.76.7.3330
Gal D, Ohashi M, MacDonald PC, Buchsbaum HJ and Simpson ER. Lowdensity lipoprotein as a potential vehicle for chemotherapeutic agents and radionuclides in the management of gynecologic neoplasms. Am. J. Obstet. Gynecol. Vol. 139: 877-885, 1981. https://doi.org/10.1016/0002-9378(81)90952-2
Filipowska D, Filipowski T, Morelowska B, Kazanowska W, Laudanski T, Lapinjoki S, Akerlund M and Breeze A. Treatment of cancer patients with a lowdensity-lipoprotein delivery vehicle containing a cytotoxic drug. Cancer Chemother Pharmacol. 29: 396-400, 1992. https://doi.org/10.1007/BF00686010
Firestone RA. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjugate Chem 5(2): 105-113, 1994. https://doi.org/10.1021/bc00026a002
Glickson JD et al. Lipoprotein Nanoplatform for Targeted Delivery of Diagnostic and Therapeutic Agents. Molecular Imaging, Vol 7 (2): 101-110, 2008. https://doi.org/10.2310/7290.2008.0012
Bijsterbosch MK, Schouten D, van Berkel TJ. Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles. Biochemistry 33: 14073-14080, 1994. https://doi.org/10.1021/bi00251a016
Lacko AG, Nair M, Paranjape S, Johnson S and McConathy WJ. High Density Lipoprotein Complexes as Delivery Vehicles for Anticancer Drugs. Anticancer Research 22: 2045-2050, 2002.
Kuai R, Li D, Chen YE, Moon JJ and Schwendeman A. High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano, 10 (3): 3015 3041, 2016. https://doi.org/10.1021/acsnano.5b07522
Mooberry LK, Sabnis NA, Panchoo M, Nagarajan B and Lacko AG. Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and Imaging. Front. Pharmacol. 7(466), 2016. https://doi.org/10.3389/fphar.2016.00466
McMahon KM et al. Synthetic High-Density Lipoprotein-Like Nanoparticles as Cancer Therapy. Cancer Treat Res. 166: 129-150, 2015. https://doi.org/10.1007/978-3-319-16555-4_6
Wang J, Jia J, Liu J, He H , Zhang H , and Li Z. Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins. Drug Deliv, 20(8): 356-363, 2013. https://doi.org/10.3109/10717544.2013.834418
Tripathy S, Vinokour E, McMahon KM, Volpert OV and Thaxton CS. High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis. Part Part Syst Charact. 31(11): 1141-1150, 2014. https://doi.org/10.1002/ppsc.201400036
Prokazova NV, Mikhailenko IA, Preobrazhensky SN, Ivanov VO, Pokrovsky SN, Timofeeva NG, Martinova MA, Repin VS and Bergelson LD. Interaction gangliosides with plasma low density proteins. Glycoconjugate J. 3, 273-286, 1986. https://doi.org/10.1007/BF01051777
Rebbaa A and Portoukalian J. Distribution of exogenously added gangliosides in serum proteins depends on the relative affinity of albumin and lipoproteins. Journal of Lipid Research 36: 564-572, 1995. https://doi.org/10.1016/S0022-2275(20)39890-4
Mikhailenko IA, Dubrovskaya SA, Korepanova OB, Timofeeva NG, Morozkin AD, Prokazova NV and Bergelson LD. Interaction of low-density lipoproteins with gangliosides. Biochim Biophys Acta. Vol. 1085(3): 299-305, 1991. https://doi.org/10.1016/0005-2760(91)90133-3
Filipovic I, Schwarzmann G, Mraz W, Wiegandt H and Buddecke E. SialicAcid Content of Low-Density Lipoproteins Controls Their Binding and Uptake by Cultured Cells. Eur. J. Biochem. 93: 51 -55, 1979. https://doi.org/10.1111/j.1432-1033.1979.tb12793.x
Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 11(6): 583-95, 1970. https://doi.org/10.1016/S0022-2275(20)42943-8
Kamps JAAM, Kruijt JK, Kuiper J and and Van Berkel TJC. Uptake and degradation of human low-density lipoprotein by human liver parenchymal and Kupffer cells in culture. Biochem. J. 276: 135-140, 1991. https://doi.org/10.1042/bj2760135
Illingworth DR, Lindsey S and Hagemenas FC. Regulation of Low-density Lipoprotein Receptors in the Human Hepatoma Cell Line Hep G2. Experimental Cell Research 155: 518-526, 1984. https://doi.org/10.1016/0014-4827(84)90211-8
Schouten D, van der Kooij M, Muller J, Pieters MN, Bijsterbosch MK and van Berkel TJ. Development of lipoprotein-like lipid particles for drug targeting: neo-high density lipoproteins. Mol Pharmacol. 44(2):486-92, 1993.
https://doi.org/10.1016/S0026-895X(25)13216-1
Counsell RE and Pohland RC. Lipoproteins as Potential Site-Specific Delivery Systems for Diagnostic and Therapeutic Agents. J. Med. Chem. 25: 1115-1120, 1982. https://doi.org/10.1021/jm00352a001
Brown MS and Goldstein JL. Regulation of the Activity of the Low Density Lipoprotein Receptor in Human Fibroblasts. Cell, Vol. 6: 307-316, 1975. https://doi.org/10.1016/0092-8674(75)90182-8
Havekes LM, Verboom H, De Wit E, Yap SH and Princen HMG. Regulation of Low Density Lipoprotein Receptor Activity in Primary Cultures of Human Hepatocytes by Serum Lipoproteins. Hepatology Vol. 6 (6): 1356-1360, 1986. https://doi.org/10.1002/hep.1840060623
Versluis AJ et al. Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice. Britsh Journal of Cancer 74: 525-532, 1996. https://doi.org/10.1038/bjc.1996.396
Lombardi P, Mulder M, De Wit E, Van Berkel TJC, Frants RR and Havekes LM. Low-density lipoproteins are degraded in HepG2 cells with low efficiency.
Edge SB, Hoeg JM, Triches T, Schneider PD and Brewer HB. Cultured Human Hepatocytes. Evidence for Metabolism of Low Density Lipoproteins by a Pathway Independent of the Classical Low Density Lipoprotein Receptor. J. Biol. Chem. Vol. 261(8): 3800-3806, 1986. https://doi.org/10.1016/S0021-9258(17)35718-6
Shaw JM, Shaw KV, Yanovich S, Iwanik M, Futch WS, Rosowsky A and Schook LB. Delivery of lipophilic drugs using lipoproteins, Ann. NY Acad. Sci. 507: 252-271, 1987. https://doi.org/10.1111/j.1749-6632.1987.tb45806.x
Zhao X, Li H and Lee RJ. Targeted drug delivery via folate receptors. Expert Opin. Drug Deliv. 5(3):309-319, 2008.
https://doi.org/10.1517/17425247.5.3.309
Marchetti C et al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. OncoTargets and Therapy 7: 1223-1236, 2014. https://doi.org/10.2147/OTT.S40947
Leamon CP and Low PS. Delivery of macromolecules into living cells: A method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA Vol. 88: 5572-5576, 1991. https://doi.org/10.1073/pnas.88.13.5572
Leamon CP and Low PS. Cytotoxicity of Momordin-Folate Conjugates in Cultured Human Cells. The Journal of Biological Chemistry Vol. 267(35): 24966 24971, 1992. https://doi.org/10.1016/S0021-9258(19)73992-1
Yoo HS and Park TG. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release. 100(2):247-56, 2004. https://doi.org/10.1016/j.jconrel.2004.08.017
Aronov O, Horowitz AT, Gabizon A and Gibson D. Folate-Targeted PEG as a Potential Carrier for Carboplatin Analogs. Synthesis and in Vitro Studies. Bioconjugate Chem. 14: 563-574, 2003. https://doi.org/10.1021/bc025642l
Reddy JA, Westrick E, Vlahov, Howard SJ, Santhapuram HK and Leamon CP. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Cancer Chemother Pharmacol. 58: 229-236, 2006. https://doi.org/10.1007/s00280-005-0151-z
Suzuki T et al. Design, synthesis, and biological activity of folate receptortargeted prodrugs of thiolate histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 17: 4208-4212, 2007. https://doi.org/10.1016/j.bmcl.2007.05.040
Henne WA, Doorneweerd DD, Hilgenbrink AR, Kularatne SA and Low PS. Synthesis and activity of a folate peptide camptothecin prodrug. Bioorganic & Medicinal Chemistry Letters 16: 5350-5355, 2006. https://doi.org/10.1016/j.bmcl.2006.07.076
Liu J, Kolar C, Lawson TA and Gmeiner WH. Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP [10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells. J Org Chem. 66(17): 5655-63, 2001. https://doi.org/10.1021/jo005757n
Leamon CP, Reddy JA, Vlahov IR, Kleindl PJ, Vetzel M and Westrick E. Synthesis and Biological Evaluation of EC140: A Novel Folate-Targeted Vinca Alkaloid Conjugate. Bioconjugate Chem. 17: 1226-1232, 2006. https://doi.org/10.1021/bc060145g
Hayama A et al. Polymeric Micelles Modified by Folate-PEG-Lipid for Targeted Drug Delivery to Cancer Cells In Vitro. J. Nanosci. Nanotechnol. Vol. 8: 1-6, 2007. https://doi.org/10.1166/jnn.2008.093
Yoo HS and Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. Journal of Controlled Release 96: 273-283, 2004. https://doi.org/10.1016/j.jconrel.2004.02.003
Zhao D et al. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. International Journal of Nanomedicine 5: 1-9, 2010.
Stevens PJ, Sekido M and Lee RJ. A Folate Receptor-Targeted Lipid Nanoparticle Formulation for a Lipophilic Paclitaxel Prodrug. Pharmaceutical Research Vol. 21(12), 2153-2157, 2004. https://doi.org/10.1007/s11095-004-7667-5
Ren D, Kratz F and Wang SW. Engineered drug-protein nanoparticle complexes for folate receptor targeting. Biochem Eng J. 89: 33-41, 2014. https://doi.org/10.1016/j.bej.2013.09.008
Wang X et al. HFT-T, a Targeting Nanoparticle, Enhances Specific Delivery of Paclitaxel to Folate Receptor-Positive Tumors. ACS Nano. 3(10): 3165-3174, 2009. https://doi.org/10.1021/nn900649v
Gabizon A, Shmeeda H, Horowitz AT and Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Advanced Drug Delivery Reviews 56: 1177- 1192, 2004. https://doi.org/10.1016/j.addr.2004.01.011
Yang T, Li B, Qi S, Liu Y, Gai Y, Ye P, Yang G, Zhang W, Zhang P, He X, Li W, Zhang Z, Xiang G, Xu C. Co-delivery of Doxorubicin and Bmi1 siRNA by Folate Receptor Targeted Liposomes Exhibits Enhanced Anti-Tumor Effects in vitro and in vivo. Theranostics 4(11):1096-1111, 2014. https://doi.org/10.7150/thno.9423
Noble GT, StefanickJF, Ashley JD, Kiziltepe T and Bilgicer B. Ligandtargeted liposome design: challenges and fundamental considerations. Trends in Biotechnology Vol. 32: 32-45, 2014. https://doi.org/10.1016/j.tibtech.2013.09.007
Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S and Gabizon A. Nuclear Delivery of Doxorubicin via Folate-targeted Liposomes with Bypass of Multidrug-resistance Efflux Pump. Clinical Cancer Research Vol. 6: 1949-1957, 2000.
Wang X et al. A Folate Receptor-Targeting Nanoparticle Minimizes Drug Resistance in a Human Cancer Model. ACS Nano. 5(8): 6184-6194, 2011. https://doi.org/10.1021/nn200739q
Feng X, Lv F, Liu L, Tang H, Xing Ch, Yang Q and Wang S. Conjugated Polymer Nanoparticles for Drug Delivery and Imaging. Materials & Interfaces Vol. 8): 2429-2435, 2010. https://doi.org/10.1021/am100435k
Duncan R. Polymer conjugates as anticancer nanomedicines. Nature Reviews Vol 6:688-701, 2006. https://doi.org/10.1038/nrc1958
Shi M, Ho K, Keating A and Shoichet MS. Doxorubicin-Conjugated Immuno-Nanoparticles for Intracellular Anticancer Drug Delivery. Adv. Funct. Mater. Vol 19: 1-8, 2009. https://doi.org/10.1002/adfm.200990046
Peters C and Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Bioscience Reports 35 art:e00225, 2015. https://doi.org/10.1042/BSR20150089
